Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Capital Expenditures (2020 - 2024)

Historic Capital Expenditures for Gain Therapeutics (GANX) over the last 5 years, with Q4 2024 value amounting to $945.0.

  • Gain Therapeutics' Capital Expenditures rose 487368.42% to $945.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $1615.0, marking a year-over-year decrease of 8948.43%. This contributed to the annual value of $22493.0 for FY2024, which is 4645.79% up from last year.
  • According to the latest figures from Q4 2024, Gain Therapeutics' Capital Expenditures is $945.0, which was up 487368.42% from $1.0 recorded in Q3 2024.
  • Gain Therapeutics' 5-year Capital Expenditures high stood at $57179.0 for Q3 2022, and its period low was -$38.0 during Q2 2020.
  • Moreover, its 5-year median value for Capital Expenditures was $8611.5 (2022), whereas its average is $13905.3.
  • Per our database at Business Quant, Gain Therapeutics' Capital Expenditures skyrocketed by 5931842.11% in 2021 and then crashed by 9984.62% in 2024.
  • Over the past 5 years, Gain Therapeutics' Capital Expenditures (Quarter) stood at $14551.0 in 2020, then decreased by 23.73% to $11098.0 in 2021, then decreased by 15.32% to $9398.0 in 2022, then tumbled by 99.8% to $19.0 in 2023, then skyrocketed by 4873.68% to $945.0 in 2024.
  • Its last three reported values are $945.0 in Q4 2024, $1.0 for Q3 2024, and $19.0 during Q4 2023.